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We have shown previously that overexpression of 
p-170 glycoprotein-mediated multidrug resistance 
plays only a minor role in conferring chemoresis-
tance to human melanoma cells. In addition to mem-
brane transporters like p-170, metabolizing enzyme 
systems have been implicated in altered drug sensi-
tivity. Recently, glutathione and associated enzymes 
have been associated with resistance to alkylating 
substances, particularly in gastrointestinal and gyne-
cologic cancers. In this study, we investigated 
whether increased levels of glutathione and related 
enzymes may play a role in chemoresistance in mel-
anoma. Levels of glutathione, glutathione S- trans-
ferase (GST), glutathione reductase, and y-glutamyl 
transpeptidase were analyzed in melanoma and non-
melanoma cell lines. In addition, 18 melanoma me-
tastases derived from skin and lymph nodes were 
examined. Levels of y-glutamyl transpeptidase were 
statistically different in cells derived from melano-
cytic tumors compared with non-melanoma cell lines 
and normal cells. In addition, GST levels in metasta-
ses derived from skin or lymph nodes were signifi-
M elanoma cells are highly resistant to chemother-apeutic agents, with response rates oflower than 30% in 11i11o [1-3) and ;, 11itro [4 ,5). T he m ech-anism of drug resistance in human melanoma cells is not known . In recent years, there has 
been increasing evidence that several m echanisms can confer 
multidrug resistance to tumor cells, including DNA topoisomerases 
or p-170 glycoprotein (reviewed in [6]) . R ecently, we showed that 
p-1.70 glycoprotein-mediated drug resistance is not of major im-
portan ce regarding chemoresistan ce in hum an melanoma [7) . 
Another possible m echanism involves glutathione (GSH) and 
drug-metabolizing e nzym es like GSH-related enzym es, which have 
been demon strated to be crucial in chemoresistance of several 
tumors, including colon, gastric, esophageal, ovarian, and cervical 
carcinomas [8 -14] . 
GSH is the predominant non-prote in thiol in mammalian cells. It 
is localized intracellularly at high concentration, and it has a broad 
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candy lower than those in permanent cell lines. 
However, levels of glutathione and related enzymes 
in metastases and cell lines fluctuated over a wide 
range, up to 40-fold, regardless of treatment status or 
origin of metastases. In a second part of the study, 
the expression of GST isoenzymes a, p,, and 11' was 
studied by immunohistology in 10 benign nevi, 29 
primary melanomas, and 39 melanoma metastases 
before and during chemotherapy. Expression of GST 
isoenzymes was increased with tumor progression, 
and GSTn was the strongest isoform expressed. How-
ever, no correlation was found between GST levels by 
immunohistochemistry and the course of tumor pro-
gression, between GST levels in metastases obtained 
before or during chemotherapy, or between GST 
levels and clinical response. These data suggest that 
alterations in glutathione metabolism and the ex-
pression of GST do not play a major role in resistance 
to chemotherapeutic drugs in melanoma. KeJI IVOrds: 
gl11 tatlr io ne-S - trausje1'as e/ y-g lutaltiJI (- tra uspeptidase/ glnta-
thioue reductase/drug resista11ce.] Invest De1·matol 105:109-
112, 1995 
range of vital fun ctions including detoxi tica ti on of xenobiotics and 
scavenging of free radicals [1 5-17) . There is also increasing evi-
dence to support a complex regulation of GSH m etabolism, 
including glutathione S-transferases (GST) and related enzymes 
[15,17) . Although several drugs affec ting the GSI-1 poo l or GST 
activity are capable of sensitizing m elanoma cells to tl1e action of 
alkylating agents in 11itro, tl1e role of the GSH/GST system in human 
m elanoma is controversial [18,19) . 
In this study, we report on the levels ofGSH, GST, ')'-glutamyl 
transpeptidase (')'-GT), and g lutatl1ione reductase (GR) in various 
malignant cell lines in comparison with HaCaT keratinocytes and 
nonnal human lymphocytes, as well as in freshly p rep ared human 
m elanoma m etas tases . Furthermore, we present data regarding the 
immunohistologic expression of GST over the course of melanoma 
tumor progression. 
MATERJ ALS AND METHODS 
Cell Culture Melanoma ce ll lines (SK-Mel-23, - 37, -1 86, and MeWo) 
were from the M emori:tl Sloan Kettering Cancer Center. Cell cultures were 
maintained as described using RPM I 1640 medium containing 10% feral 
bovine serum [20]. All m elan oma cell Lin es used in the present study ha ve 
been characterized previously regarding their differentiation characteristics 
according to Houghton et a/ [21] . Ln additio n , mouse melanoma cell Lines 
B16 Fl and B1 6 FlO and no rmal human melanocytes were studied. For 
con1pari son , \VC in vestigated ce ll s of n o n-tnc lanocytic origin including 
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Table I. Levels of GSH and Related Enzymes in Metastases and Cell Lines" 
GST (mU/mg Protein) GR (mU/mg Protein) )1-GT (mU/mg Pro te in) GSH (J-Lg/mg Protein) 
Source Median Range Median Range Median Range Median Range 
Lymph nodes (N 11) 14.7 5.5-l1.9.2 22.0 9.7-36.9 0.13 0.21-2.86 13.0 9.0-17.4 
Skin (N = 6) 37.4 3.1-49.7 23.5 15.4-28.0 0.74 0.0-0.49 21.0 6.4-28.2 
Melanoma (N = 6) 142.8 36.1- 227 29.6 25.3-33.3 0.45 0.07-1.1 8 .75 6.8 - 9.7 
Non-melanoma (N = 4) 75.2 28.4-116.1 29.3 20.1-37.8 7.3 1.2-12.9 14.3 5.2-25.1 
Normal cell s (N = 7) 66.8 16.2-181.2 39.2 10.3-92 .0 2.7 0.0-5.4 13 .8 10.6-17.1 
'
1 Biochemical assays as described in Nlaterin ls ami Methods were performed using fres hl y obta in ed melanoma m e t01stascs derived from lyn1ph node~ and skin, malignant ccllliucs 
of mclan ocytic origin (McWo. SK-Mcl-23, SK-Mcl-37, M 14, B16FI, ll16F1 0) and non-mclanocytic origin (1-IM C- 1, HepG2, 1<.562, U937). and normal cells (norm:tl human 
kcra rinocytcs. no rmal human mch111ocytc s. 1-Ja CaT keratinocytcs, and pcriphcr:tl blood lymj.Jhocytcs of fo ur healthy donors). 
hematopoietic ce.ll lines K562 , HMC-1, and U937 and nonnal human 
keratinocytes as well as l-In CaT keratinocytcs. Ficoll-separated lymphocytes 
of four healthy donors and 18 fres hly prepared human melanoma metastases 
were analyzed. 
Patient Specimens and Documentation For immunohistologic stud-
ies, 10 nevi (three dysplastic, six compound, one dermal), 29 primary 
tnalig nan t n1clanomas of various tun1or th.ickness (n1edian tUJnor thickness 
2. 1 mm}, and 39 melanoma metastases of21 patients were evaluated before 
(n = 27) and during chemotilCrapy (n = 12). Patients were treated with 
dacarbazinc (n = 1 0), Vindcsinc (n = 4}, 5-fluorouracil (n = 4}, cisplat:in 
(n = 1}, and Fotemustine (n = 1). 
Lysates of cell lines and fresh melanoi11a cell preparations were eva luated 
for the biologic activity of GSl-1-rclated enzymes. All patients entering tlus 
part of the study had advanced metastatic melanoma. Eighteen tumor 
speciincns were co llected from patients undergoing surgery as part of their 
diagnostic work-up or treatment of their disease. All specimens were 
confmncd on histology to be met:~ stases of malignant melanomas. Mela-
noma metastases were derived from skin (n = 6), pleural efHusion (n = 1} , 
and lymph nodes (n = 11). Fresh tumor specimens were placed in RPMI 
1640 cu lture medium. Single-cell suspensions were obtained by mechanical 
and enzymati c dissocia tion. as described before (4] . 
Immunohistology AU tissue s•nnples were frozen rapidly in liquid 
nitrogen and kept •1 t - 80°C. Cryostat sections (4-1 0 !J.m) were prepared at 
- 25 °C, placed on poly-L-lysine-coated slides, dried for 20 min , ~ixcd with 
icc- co ld acetone. and used either immediately o r after storage (for up to 5 
d) at - 20°C. Defore sta ining, the sections were fixed for 1 0 min in acetone 
at room tcmpernture and subsequently sta ined by the standard alkaline 
phosphatase-anti-alkaline phosphatase technique, as described previously 
[22). 
A 11tibodics: Poiyclonai. monospecific hyperimmunc rabbit sera detecting 
GST isoenzymes a, J-L, and 7r were obtained from Mcdac (Hamburg, 
Gem1any}. In addition, a polyclonal rabbit an tiserum and two mouse 
monoclonal an tibodies (161-18, 8F1) detecting GST7r were generously 
provided by Or. R . Kantor [23]. Normal human t11ammary tissue (anti-
GSTa), normnl li ver (anti-GST!J.) , and nom1al human kidney (anti-GST7r) 
were used as positive contro ls. Antibody specifici ry of all tl1ese reagents was 
demonstrated by Westen> blot analysis ([23]; own data not shown). 
El!nluntiou of Staiucd Scctious: Quantitative evaluation was done by count-
ing all positive cell s in ten microscopic fields (magnification X 100). A 
standard eva luation form was designed, and two investigators read all 
sections and scored the percentage of positive cell s semiquantitatively, using 
four different categories (-, ( + ), +, + + ). Discrepancies in interpretation 
were resolved by a second parallel reading of the slides. Only sections 
reacting with more than one antibody were considered positive. 
BiochCJnical Assays 
Cell Lysis: Cell lysares were prepared fi·om cell suspensions and monolay-
c rs. Ce ll n1onolaycrs were trypsinized and added in1n1ediatcly to an equa l 
vo lume of l"l...PMI 1640 containing 10% fetal bovine sernm. Cell s were 
was hed twice with 0.9% NaCl, and the pellet was resuspended in 20 mM 
Tris containing 1 mM dithiothreitol (pH 7 .4} . T he resuspended cells were 
sonicated three times for 20 seconds on icc with an ul trasonifi er and 
subsequently centrifuged nt 14,000 rpm for 20 min at 4 °C. Pellets were used 
immediately or were stored at - 80°C until use. 
GSH Assay: GSH levels were measured according to Tietze [24] with the 
followin g modifications. Sulfosa li cylic acid was added to 100 J-Ll cell lysate 
at a fina l concentration of 4% (w/v), and cellular proteins were left on icc 
for 1 h for precipitation . After centrifugation at 14,000 rpm for 15 min in an 
Eppcndorf centri fuge, protein contents of the supernatants were de termined 
using the BCA assay (Pierce, O ud-Beijerland, The Netherlands) and 
subsequently analyzed for GSH levels. The assay for total GSJ-1 (oxidized 
and reduced) was carried out by an enzyme-recycling method. All assays 
were performed in mitrotitcr plates, and the rate of color formation at 410 
nm was monitored. Total GSJ-1 concentration was expressed as f.Lg GSH/mg 
protein. 
CST Assay: Total GST activity was assayed by the method of Habig el a/ 
[16]. One hundred microliters of cell lysate was incubated in 2 mM GSI-1 
and 2 mM 1-chloro-2,4-dinitrobenzene in 125 mM phosphate bufFer (pH 
6.5) at a final volume of 1 mL The formation of S-2,4-dinitrophenylgluta-
thione was measured spectrophotometrica lly at a wavelength of 340 mn 
(extinction coefficient e = 9.6 cm - 1 • M - 1), and results were expressed as 
mU/mg protein. A unit of enzymatic activity was defined as the amount of 
enzyme catalyzing the formation of 1 !J.mol of S-2,4-dinitrophenylgluta-
thione per min. 
CR Assay: GR was assayed in ce ll lysates by the method of Carlberg and 
Mannervik [25]. W e added 100-200 f.Ll cell lysate to 900 J-Ll incubation 
mixture (1 mM oxidized GSH, 0.5 mM ethylenediaminetetraacetic acid, 0.1 
mM reduced nicotinamide adenine dinucieotidc phosphate in 1 25 mM 
phosphate buffer, pH 7.2). The formation of reduced nicotinamide ade1line 
dinucleotide was monitored spectrophotometrically at an absorbance of340 
nm . Results were expressed as mlJimg protein. 
-y-CT Assay: )1-GT was measured usi ng the metl1od of T"tc and Meister 
[26]. Cell lysate, 100-200 J-Ll, was added to a fmal volume of l ml 50 mM 
Tris bufFer (pH 8.0} containing 5 mM L-a-glutamyl-p-nitroanilidc, 20 mM 
glyclglyc inc, and 75 mM NaCL Absorbance was measured every 1 5 min 
over 2 h at 4l 0 nm (extinction coefficient e = 10.4 em - • - M - •). Results 
were expressed as mU/mg protein. 
Statistics Statistical sign i.ficancc of the data w"s calculated using the 
modiJied Wilcoxon signed-rank test. T he procedure was to convert the 
observations to rank order and then calcu late the t statistics by using ranks 
instead of the original observations . 
RESULTS 
GSH Levels and Activities of Related Enzyme Are Not 
Related to Clinical Parameters We performed bioch emical 
measurements oflevels of GSH, GST, y-GT, and GR of si:x human 
m e lanoma cell lines, five non-melanoma cell iines, GSH, freshly 
isolated meJanocytes, ke ratinocytes, and lymphocytes, and of 18 
melanoma m etastases. In all sp ecimens and cell lines, the results 
showed a highly individual and c h aracte ri stic profile of GSH levels 
and related enzymes, with a wide Auctuation of values e ven 
b etween vario us metastases of the same patient. Meati levels and 
ranges are given in Table I. 
The GST levels ranged from 3.15 to 226.99 mU/mg protein and 
were significantly lower in freshly isolated metastases than in 
permanent cell lines (p < 0.05) (Table 1). GR varied from 10.3 to 
93.0 mU/mg protein, with no statistical difference between cell 
lines and fi·esh specimens or between melanoma and non-mela-
noma tissue. y-GT ranged from 0.00 to 12.87 mU /mg protein. 
There was a significant difference between transformed cells of 
m e lanocytic origin (fi·esh metastases and melanoma cell lines) 
versus non-melanoma cell lines (p < 0.05) (Table 1). GSH levels 
ranged from 5.0 to 25 .0 I.Lg/mg protein. 
An overall statistica l analysis re vealed no corre lation between 
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Figure 1. Increased expression o f GST isoen-
zytnes during tuntor progression. lmmu.noh.isto-
logic detection of GST isoenzym es a, J.t, and 7r 
g rouped sen1iquanti tativcly in fo ur different catego-
ries [0 , ( + ), +, + + ), as described in Materials a11d 
Metlwds. A, expression in benign nevi; j indicates 
positive sta.inin_g in junctional part of the nevus. B, 
immunohistologic e"-"Pression in primary cutaneous 
n1alignan t n1clano n1a. Melano n1as with tun1or thick-
n ess l;,'TCater than 1.5 mm are indica ted (opw circles). 
C, immunohistochemical expression in m elanoma 
n1ctasta ses , including n1c lanon1a n1ecastascs wi tho u t 
pretrea tment (closed boxes) and metastases removed 
during or after chemotherapy (ope11 boxes). 
GSH levels and enzym e activities m easured and clinical parameters, 
e.g., tumor subtype, tumor thickness, C lark level, localization , or 
trea tment status. 
Increased Immunohistologic Detection of GST Isoenzymes 
W it h Melanoma Progrcss~on GST isoenzymes a, JL, and 7r 
were examined i.I1 10 benign nevi, 29 primary m elanomas, and 39 
m elanoma meta stases derived fi·om 21 patients using SL"X difFerent 
antibodies . Expression of GST isoenzym es in nevi was low or 
undetectable in e igh t of l 0 specimens (Fig 1A). The junctional part 
of two dysplastic compound nevi stai.I1ed for all three GST isoforms. 
In primary cutaneous m e lanomas and m elanoma m etastases , all 
three GST isoenzym es were expressed, with GST7r being stronger 
than GSTJL and GSTa. D l1l'ing twnor progression from nevi to 
primary melanoma to metastasis, there was a trend toward higher 
expression of all GST isoforms (Fig 1). GST levels in m elanom a 
metastases did not difFer signifi cantly when analyzed for pretreat-
ment status (none versus chemotherapy) (Fig 1C). No statistical 
correlation between GST7r and a chemotherapeutic drug was 
found. 
No Correlation o f Clinical Status With Expression of GST 
Isoenzymes Was Detected by Immunohistology A compar-
ison of the GST isoenzym e immunohistochemical profile in pri-
nla.ry human m elanom a and m elanoma metastases versus tumor 
stage or respo nsiveness to chemotherapy revealed no correlation s. 
There w ere also no statistical difFerences in staining between the 
groups of samples from treated and untreated patients. Metastases 
obtained fi·om the sam e patient (n = 7) at the sam e time p oi.I1t or 
during chemotherapy showed a hig h degree of heterogeneity of 
GST isoenzyme levels unrelated to treatment status or clinical 
respon siveness (data n ot shown) . 
DISCUSSION 
In the las t decade, several gro ups have found a correlation between 
increased levels of GSTs and chemoresistance in various tumors 
[10,12,19]. T he fun ctional role of GSTs in chem oresistance has 
been questioned, however, because many multidrug-resistant cell 
lines fail to overexpress the enzym es. Furthermore, results of 
molecular biologic gene transfection experiments generated only 
variable and low levels of resistance to alkylatin g agents [27,28]. 
Only a few studies have been conducted determining the role of 
alterations in GSH m etabo lism u1 melanoma cell resistan ce, partic-
ularly to alkylating agents [29 - 31] . However, the importance of the 
mechanism has not been clarified entirely for this tumor. In the 
present study, o ur results revealed o nly a few correlations between 
levels of GSI-I or its re lated en zym es and tumor progression or 
clinical treatm ent status. T here were no statistical difFe rences 
regarding treated and untreated patients. DifFeren ces for certain 
e nzymes cou.ld be iden tified between cell lines and fi·es h tumor cell 
preparations. T his is in agreement with the o bservation that levels 
of GSI-1 and rela ted enzym es arc not sta ble after prolonged times in 
tissue cu lture [3 2] . 
In earlier studies on GST in me lanomas, GST7r was quantified as 
the isoenzyme m ainly expressed i.I1 m etastatic melanoma [31,33, 
34], in agreement with o ur results. Fu rtherm ore, GST levels in nevi 
were lower than those in prin1ary mel anoma and melanoma 
m etastases . Levels of GSI-1 and related enzym es in m etastases were 
not afFected by the pretreatment status. 
GSH and GST (29] and GR levels (35] have been CO!Telated with 
the m e lanotic state of the cells because m elanogenesis is associated 
with modifications in the intracellular redox balance and because 
the GSH/GST system migh t be involved in adaptation to oxidative 
stress resulting fi·om melanogenesis. In o ur experim ents, we could 
not fu1d such a correlation. Only tl1e expression of y-GT differed 
sig1Tilicantly w hen m elanotic cell s were compared with non-mela-
notic cells . y-GT activity has been tho ugh t to correlate with the 
developmental cycle of m elanogenic cell s and seem ed to parallel 
tyrosine activity [3 6]. Furtherm ore, higher levels of GST, GR, and 
y-GT have been detected in metastatic compared witl1 non-
m etastatic variants of the mouse mel an oma cell li ne B16 [30] . 
Although our results do not sh ow significant correlations be-
tween alterations in GSH m etabolism and tumor progression or 
drug sen sitivity, the data do not entirely exclude a role of these 
m echanism s in melanoma chem oresistan ce, as an increased capacity 
for GSH syntl1esis of ilie tumor cells in response to cytotoxic drugs 
would not be detectable i.I1 our experiments. N evertheless, the data 
agree with results fi·om oth er highly multidrug-resistan t tumors 
such as breast and lung cancers, for w hich the GSH/ GST system 
has been shown not to be involved in chemoresistance [32,3 7]. 
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